The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.
The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.
BNT162b2 vaccine effectiveness against symptomatic infection modest and declined rapidly, was higher after booster dose in teens.
No significant difference seen in cycle threshold values based on variant, regardless of vaccination status.
Stress surrounding the pandemic declined in US children after vaccinations were rolled out for adults.
The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.
Among fully vaccinated adults, diagnosis of a psychiatric disorder linked to increased incidence of SARS-CoV-2 breakthrough infection.
However, higher risk seen for breakthrough infections and severe outcomes, especially for hematologic malignancies.
The COVID-19 pandemic has underscored how easy it is for disreputable and non-authoritative sources to spread wrong and possibly dangerous medical information.
Nursing home residents continue to be more vulnerable both because of their age and underlying medical conditions.
